A reasonable period should be allowed to elapse before an active substance is approved, in order to permit Member States, interested parties, and the Commission where appropriate, to prepare themselves to meet the new requirements entailed.
Recital 8, Commission Implementing Regulation (EU) No 945/2013 of 2 October 2013 to approve cyperme…
In force